Arbutus Biopharma’s (ABUS) Buy Rating Reaffirmed at HC Wainwright

Arbutus Biopharma (NASDAQ:ABUS – Get Rating)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $6.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 109.79% from the company’s previous close. HC Wainwright also issued estimates for Arbutus Biopharma’s FY2027 earnings at ($0.11) EPS.

Separately, Chardan Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Arbutus Biopharma in a research note on Friday.

Arbutus Biopharma Trading Up 1.8 %

NASDAQ ABUS opened at $2.86 on Friday. The stock has a market capitalization of $428.86 million, a price-to-earnings ratio of -6.09 and a beta of 2.26. Arbutus Biopharma has a twelve month low of $1.85 and a twelve month high of $3.22. The stock has a 50-day moving average of $2.70 and a 200 day moving average of $2.46.

Institutional Trading of Arbutus Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. Alliancebernstein L.P. increased its position in Arbutus Biopharma by 54.4% in the 4th quarter. Alliancebernstein L.P. now owns 49,100 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 17,300 shares during the period. State of Wyoming grew its holdings in Arbutus Biopharma by 27.6% during the fourth quarter. State of Wyoming now owns 41,907 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 9,075 shares during the period. Moneta Group Investment Advisors LLC lifted its position in shares of Arbutus Biopharma by 114,139.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 14,952,790 shares of the biopharmaceutical company’s stock valued at $34,840,000 after acquiring an additional 14,939,701 shares during the period. Virtu Financial LLC acquired a new stake in shares of Arbutus Biopharma during the 4th quarter valued at approximately $103,000. Finally, Tejara Capital Ltd purchased a new stake in Arbutus Biopharma during the fourth quarter worth $466,000. 31.03% of the stock is owned by hedge funds and other institutional investors.

About Arbutus Biopharma

(Get Rating)

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.